
Quarterly report 2025-Q3
added 11-04-2025
GoodRx Holdings Cash Flow 2011-2026 | GDRX
Annual Cash Flow GoodRx Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
184 M | 138 M | 147 M | 179 M | 131 M | 83.3 M | 45.3 M | - | - | - | - | - | - | - |
Depreciation & Amortization |
69.5 M | 108 M | 54.2 M | 34.5 M | 18.4 M | 13.6 M | 9.81 M | - | - | - | - | - | - | - |
Accounts Payables |
14.1 M | 36.3 M | 17.7 M | 17.5 M | 10.3 M | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
146 M | 144 M | 117 M | 118 M | 68.7 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow GoodRx Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | 9.41 M | - | - | 42.6 M | - | - | 32.3 M | - | - | 81.2 M | 30.1 M | - | - | 80.4 M | 45.5 M | - | 116 M | 83.8 M | 45.6 M | - | 66.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
21.4 M | 19.7 M | 20.9 M | 17.5 M | 17 M | 15.9 M | 33 M | 16.1 M | 14.9 M | - | 14 M | 13.3 M | 11.4 M | - | 10.2 M | 8.37 M | 5.36 M | - | 5.16 M | 4.52 M | 4.34 M | - | 3.61 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
28.7 M | 25.4 M | 15.3 M | 12.4 M | 16.9 M | - | 32.9 M | 6.8 M | 12.4 M | 17.7 M | - | 16.8 M | 12.8 M | 17.5 M | 17.3 M | 18.4 M | 15.1 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 7.85 M | 7.85 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
204 M | 189 M | 160 M | 131 M | 162 M | - | 121 M | 123 M | 116 M | 117 M | - | 123 M | 123 M | 118 M | 98.5 M | 87 M | 74.4 M | 68.7 M | 68.7 M | 68.7 M | 68.7 M | 48.1 M | 48.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company GoodRx Holdings, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Health information services sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Accolade
ACCD
|
- | 0.29 % | $ 206 M | ||
|
Change Healthcare
CHNG
|
- | - | $ 9.03 B | ||
|
Phreesia
PHR
|
$ 11.27 | -0.13 % | $ 615 M | ||
|
Cerner Corporation
CERN
|
- | - | $ 27.9 B | ||
|
American Well Corporation
AMWL
|
$ 5.77 | 0.17 % | $ 92.6 M | ||
|
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | ||
|
Covetrus
CVET
|
- | - | $ 2.94 B | ||
|
Schrödinger
SDGR
|
$ 11.51 | -0.52 % | $ 845 M | ||
|
iCAD
ICAD
|
- | - | $ 102 M | ||
|
Teladoc Health
TDOC
|
$ 5.57 | 2.87 % | $ 982 M | ||
|
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | ||
|
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | ||
|
Premier
PINC
|
- | - | $ 2.33 B | ||
|
Omnicell
OMCL
|
$ 34.87 | 1.19 % | $ 1.61 B | ||
|
OptimizeRx Corporation
OPRX
|
$ 7.15 | 5.38 % | $ 122 M | ||
|
Evolent Health
EVH
|
$ 2.28 | 1.11 % | $ 214 M | ||
|
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | ||
|
SCWorx Corp.
WORX
|
$ 0.13 | 3.86 % | $ 190 K | ||
|
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | ||
|
Zhongchao
ZCMD
|
$ 1.82 | 0.28 % | $ 9.47 M | ||
|
R1 RCM
RCM
|
- | - | $ 3.81 B | ||
|
Akerna Corp.
KERN
|
- | - | $ 161 M | ||
|
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | ||
|
Health Catalyst
HCAT
|
$ 1.11 | 0.91 % | $ 77.6 M | ||
|
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | ||
|
HealthEquity
HQY
|
$ 81.92 | -0.23 % | $ 7.06 B | ||
|
HealthStream
HSTM
|
$ 21.18 | 1.0 % | $ 644 M | ||
|
10x Genomics
TXG
|
$ 20.98 | 5.91 % | $ 2.46 B | ||
|
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | ||
|
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | ||
|
Progyny
PGNY
|
$ 17.65 | -2.22 % | $ 1.51 B | ||
|
So-Young International
SY
|
$ 3.11 | 6.87 % | $ 247 M | ||
|
Veeva Systems
VEEV
|
$ 178.22 | -0.5 % | $ 29.2 B |